10-QPeriod: Q2 FY2002

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2002

Filed August 13, 2002For Securities:GILD

Summary

Gilead Sciences, Inc. reported significant revenue growth in the second quarter and first half of 2002, driven primarily by the strong performance of Viread®, its HIV treatment. Total revenues more than doubled year-over-year in the second quarter, reaching $109.4 million, and increased by 73% for the first half to $187.8 million. This revenue acceleration is a positive sign for investors, indicating successful market penetration for a key product launched in late 2001. While the company continues to invest heavily in research and development and selling, general, and administrative expenses, particularly for Viread's commercialization, it has moved towards profitability in the current periods compared to the prior year's losses. Operationally, Gilead has shown improved cost management, with cost of goods sold as a percentage of net product sales decreasing due to a favorable product mix with Viread's higher margins. Research and development expenses have decreased year-over-year, largely due to the completion of Viread's Phase III clinical program and the divestiture of its oncology assets. Despite increased SG&A to support product launches, the company's strategic focus on key antiviral products appears to be yielding positive financial results, though it remains to be seen if this trend will lead to sustained profitability.

Key Highlights

  • 1Total revenues surged to $109.4 million in Q2 2002 and $187.8 million in H1 2002, a substantial increase from $50.7 million (Q2 2001) and $108.5 million (H1 2001), driven by new product sales.
  • 2Viread® sales were a significant growth driver, contributing $44.7 million in Q2 2002 and $71.9 million in H1 2002, representing 48% and 44% of net product sales respectively, a stark contrast to minimal sales in the prior year.
  • 3AmBisome® sales continued to grow, increasing 23% year-over-year in Q2 2002, though its contribution to total product sales decreased as Viread gained traction.
  • 4The company achieved operating income of $19.2 million in Q2 2002 and $12.3 million in H1 2002, a significant turnaround from the operating losses of ($33.9) million (Q2 2001) and ($59.7) million (H1 2001).
  • 5Research and Development expenses decreased by 30% in Q2 2002 and 32% in H1 2002, primarily due to the completion of Viread's Phase III trials and the sale of oncology assets.
  • 6Selling, General, and Administrative (SG&A) expenses increased by 40% in Q2 2002 and 58% in H1 2002, reflecting increased global marketing efforts and sales force expansion for Viread.
  • 7Cash, cash equivalents, and marketable securities stood at $559.5 million as of June 30, 2002, providing a solid liquidity position.

Frequently Asked Questions

The primary driver of Gilead's significant revenue growth is the strong performance of Viread®, its HIV treatment, which was launched in late 2001. Viread's sales contributed substantially to product sales, offsetting the reduced proportional contribution of AmBisome® and marking a significant turnaround from minimal sales in the prior year.

Research and Development (R&D) expenses decreased due to the completion of the Phase III clinical program for Viread and the divestiture of the company's oncology assets. While this reflects successful completion of certain development cycles and strategic portfolio adjustments, Gilead continues to invest in its pipeline, particularly for Hepatitis B and HIV, indicating ongoing commitment to innovation.

Gilead Sciences maintains a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $559.5 million as of June 30, 2002. The company also achieved operating income in the current periods, a significant improvement from the previous year's losses, suggesting a path towards greater financial stability.

Yes, Gilead has a key licensing agreement with GlaxoSmithKline (GSK) for adefovir dipivoxil (for hepatitis B) in various territories, which includes an upfront payment and potential milestone payments. They also have ongoing collaborations with Fujisawa for AmBisome® and Roche for Tamiflu®, which contribute to royalty and contract revenues.